BioSpace News Archive

Drug Development

Cannabis-Derived MS Treatment Disappoints in Phase III Trial

The Phase III study of Jazz Pharmaceuticals cannabis-derived MS Sativex failed to achieve the primary endpoint of an improvement in muscle tone in patients.

June 29, 2022
·
2 min read
·
Vanessa Doctor, RN
Policy

FDA Advisory Committee Calls For Updated COVID-19 Boosters to Quell Omicron

Voting 19-2, the Vaccines and Related Biological Products Advisory Committee favored redesigning booster shots to include the coronavirus’ Omicron variant.

June 29, 2022
·
2 min read
·
Tristan Manalac
Business

Generian, Mitobridge (Astellas) Partner to Expand Playbook of what is Druggable

Generian and Mitobridge, a wholly-owned subsidiary of Astellas Pharma, announced a collaboration to discover and develop novel small molecules for undruggable therapeutic targets.

June 29, 2022
·
4 min read
·
Hayley Shasteen
Drug Development

Icosavax Preps IND Application for RSV Vaccine Following Positive Data

Icosavax posted positive topline interim data from its Phase I/Ib trial of IVX-121, its candidate virus-like particle vaccine against the respiratory syncytial virus in young and older adults.

June 29, 2022
·
2 min read
·
Vanessa Doctor, RN
ARCH Defies Biotech Market Slowdown with New $3B Fund

“Science doesn’t care what markets are doing, and science moves forward,” ARCH Co-founder and Managing Director Robert Nelsen said in a statement.

June 29, 2022
·
3 min read
·
Mark Terry
Researchers Discover Candida auris Can Reproduce Sexually

A deadly fungus–Candida auris (C. auris)–has shaken up the biological world with its ability to reproduce sexually. What can be its dangers and what are the next steps? Know it all here.

June 29, 2022
·
2 min read
·
Jazmine Colatriano M.S.
New Research Explores the Role of Oxygen in Cancer Growth

New research by investigators at Columbia University and MIT describes how cancer cells often depend upon the importation of fat for continued growth and division.

June 29, 2022
·
3 min read
·
Mark Terry
Drug Development

Axsome Advances MDD Drug, Explores New ADHD Treatment

Axsome hosted an investor day event to provide an update on plans for Sunosi and other developmental assets, including MDD treatment AXS-05.

June 29, 2022
·
2 min read
·
Alex Keown
Business

Money on the Move: ReCode, MiroBio & More Target Technology

This week money went towards more advanced rounds of financing for drugs and technology that have already shown a lot of promises.

June 29, 2022
·
4 min read
·
Hannah Chudleigh
Drug Development

89bio Seeks $94.5M for Phase III SHTG Trial

89bio reported positive topline results from ENTRIGUE Phase II trial of pegozafermin in patients with severe hypertriglyceridemia.

June 29, 2022
·
2 min read
·
Alex Keown